Regeneron: Antibody cocktail cut COVID-19 death risk in half for hospitalized patients
Tarrytown's Regeneron presented some promising data Tuesday from its antibody cocktail.
•
Dec 30, 2020, 3:31 AM
•
Updated 1,305 days ago
Share:
More Stories
Hometown Heroes in the Hudson Valley
2ds ago1:28
Medical experts recommend to still take precautions following CDC's revised COVID isolation guidelines
147ds ago1:52
Judge: 3 men convicted in COVID-19 relief aid fraud
168ds ago1:47
Wondrous Things store in Briarcliff Manor to close after 34 years; everything 25% off
295ds ago0:28
Rockland small businesses get COVID-19 reimbursement grant
295ds ago
Nobel in medicine goes to 2 scientists whose work enabled creation of mRNA vaccines against COVID-19
298ds agoHometown Heroes in the Hudson Valley
2ds ago1:28
Medical experts recommend to still take precautions following CDC's revised COVID isolation guidelines
147ds ago1:52
Judge: 3 men convicted in COVID-19 relief aid fraud
168ds ago1:47
Wondrous Things store in Briarcliff Manor to close after 34 years; everything 25% off
295ds ago0:28
Rockland small businesses get COVID-19 reimbursement grant
295ds agoNobel in medicine goes to 2 scientists whose work enabled creation of mRNA vaccines against COVID-19
298ds agoTarrytown's Regeneron presented some promising data Tuesday from its antibody cocktail.
According to its own research, the company's antibody cocktail cut the risk of death by 50% in patients currently in the hospital that require low-flow oxygen.
Initial data showed it had to be used in non-hospitalized patients only.
Last month, the FDA granted an emergency-use authorization for the antibody cocktail.
